One step at a time. OCRX has to get to phase-3, succeed in one or more phase-3 trials, and then submit an NDA. So, potential FDA approval is several years away.
Still, the valuation is so cheap that the share price could soar on positive news, such as FDA acceptance of a trial design for phase-3.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”